Ticker Details
Viking Therapeutics, Inc. Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.
IPO Date:	April 29, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.59B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.47 | 3.34%
Avg Daily Range (30 D):	$0.71 | 2.20%
Avg Daily Range (90 D):	$0.91 | 2.83%

Institutional Daily Volume
Avg Daily Volume:	1.88M
Avg Daily Volume (30 D):	1.95M
Avg Daily Volume (90 D):	2.39M

Trade Size
Avg Trade Size (Sh.):	113
Avg Trade Size (Sh.) (30 D):	71
Avg Trade Size (Sh.) (90 D):	76

Institutional Trades
Total Institutional Trades:	5,232
Avg Institutional Trade:	$2.74M
Avg Institutional Trade (30 D):	$3.15M
Avg Institutional Trade (90 D):	$2.47M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.42M
Avg Closing Trade (30 D):	$6.91M
Avg Closing Trade (90 D):	$6.86M
Avg Closing Volume:	247K

News

May 26, 2026 @ 8:04 AM Prediction: These 2 Obesity Drug Stocks Could Doub... Source: Adria Cimino

May 25, 2026 @ 9:05 AM Eli Lilly Just Made a Game-Changing Move in the Bi... Source: Adria Cimino

May 23, 2026 @ 8:31 PM Is Viking Therapeutics a Top Takeover Target? Source: Jeff Siegel

May 22, 2026 @ 7:15 AM 2 Stocks That Could Realistically Double by 2030 Source: Prosper Junior Bakiny

May 21, 2026 @ 11:05 AM Viking Therapeutics to Participate at Upcoming Inv... Source: Prnewswire

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.19	$-1.39	$-3.19
Diluted EPS	$-3.19	$-1.39	$-3.19
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-359.64M	$-157.66M	$-359.64M
Operating Income / Loss	$-393.34M	$-164.74M	$-393.34M
Cost of Revenue
Net Cash Flow	$139.14M	$65.43M	$139.14M
PE Ratio